Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    "Nephrogenic Systemic Fibrosis"
Show Display Options
Rank Status Study
1 Terminated Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)
Conditions: Nephrogenic Fibrosing Dermopathy;   Nephrogenic Systemic Fibrosis
Intervention: Procedure: Plasmapheresis
2 Enrolling by invitation Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels
Conditions: Nephrogenic Systemic Fibrosis;   Nephrogenic Fibrosing Dermopathy
Intervention:
3 Completed Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec
Condition: Nephrogenic Systemic Fibrosis
Intervention: Drug: Imatinib mesylate (Glivec)
4 Suspended Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
Conditions: Nephrogenic Systemic Fibrosis;   Renal Insufficiency
Intervention:
5 Completed Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis
Condition: Nephrogenic Systemic Fibrosis
Intervention:
6 Enrolling by invitation Nephrogenic Systemic Fibrosis With Gadollinum
Conditions: Nephrogenic Systemic Fibrosis;   Renal Failure
Intervention: Drug: gadollinum
7 Unknown  Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis
Condition: Nephrogenic Systemic Fibrosis
Intervention: Drug: Imatinib mesylate
8 Completed Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR
Condition: Nephrogenic Systemic Fibrosis
Intervention: Drug: Ablavar
9 Completed
Has Results
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Conditions: Fibrosis;   Kidney Failure;   Renal Insufficiency
Intervention: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882)
10 Completed Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
Condition: Renal Insufficiency
Intervention:
11 Completed
Has Results
Primovist / Eovist in Renally Impaired Patients
Condition: Contrast Media
Intervention: Drug: Gadoxetic acid disodium (Primovist, BAY86-4873)
12 Completed Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease
Condition: Renal Insufficiency
Intervention:
13 Completed Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
Condition: Renal Insufficiency
Intervention:
14 Active, not recruiting Safety of Gadovist in Renally Impaired Patients
Conditions: Fibrosis;   Renal Impairment
Intervention: Drug: Gadobutrol (Gadovist, BAY86-4875)
15 Completed
Has Results
Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)
Conditions: Chronic Kidney Disease;   Renal Insufficiency
Intervention: Drug: Omniscan

Indicates status has not been verified in more than two years